

26 June 2014

ASX ANNOUNCEMENT

Green Whistle receives regulatory approval in South Africa

Medical Developments International Limited (ASX:MVP) has received approval from the Medicines Control Council (MCC) in South Africa to market and sell its inhaled analgesic product, 'Penthrox' for pain relief from trauma and surgical procedures.

The approval gives MVP's partner in South Africa, LINK Healthcare Pte Ltd (through its wholly owned subsidiary Equity Pharmaceuticals Pty Ltd), the right to start selling 'Penthrox' (marketed as 'Penthrop' in South Africa) effective immediately. LINK Healthcare estimates the size of the prescription only analgesic market in South Africa is \$90 million.

The approval in South Africa opens the regulatory pathway for approvals to sell Penthrox in Namibia, Botswana, Lesotho, Swaziland, Angola, Malawi, Mozambique and Zambia. LINK Healthcare advise the approval process in these countries will take less than 12 months because South African regulators have registered Penthrox for sale. MVP CEO, Mr. John Sharman said "this approval is a great opportunity for our company and could open the door to Africa'.

Mr. Sharman said 'this registration is the first indication we have received that the work done on our clinical trials in England for our regulatory dossier in that country, will enable our company to get approval to sell Penthrox in countries other than the EU where we are currently being assessed. MVP is in discussion with pharmaceutical companies in various countries in Europe and elsewhere and we are hopeful we can conclude a number of licensing and distribution agreements in the coming months."

Enquiries:

David Williams
Chairman
0414 383 593

John Sharman
Chief Executive Officer
03 9547 1888

About Pentrox

'Penthrox' is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. 'Penthrox' has been used safely and effectively for more than 30 years in Australia with excess of 7.0 million units sold. There is growing interest in 'Penthrox' being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast acting minor trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

About Link Healthcare (Australia, New Zealand, Southern Africa, Singapore, Hong Kong & Japan)

LINK Healthcare is a privately owned specialist pharmaceutical and medical technologies business. LINK's mission is to strive for excellence in the marketing of a vitally important and unique range of specialist products that enhance the well-being of people throughout the regions of Australia, New Zealand, Asia and Southern Africa.

LINK provides exceptional regulatory, sales, marketing, customer service and supply chain infrastructure and is partnered with major blue chip pharmaceutical companies from around the world, allowing the company to offer a unique and substantial portfolio of 'medicine that matters.'

LINK Healthcare has an extensive range of prescription pharmaceuticals in essential therapeutic areas including Allergy, Anaphylaxis, Analgesia/Anaesthesia, Anti-infective, Anti-retroviral, Cardiology, Endocrinology, ENT, Gastroenterology, Intensive care, Metabolic disease, Neurology, Oncology, Orphan Drugs, Palliative care, Psychiatry, Radiography, Transplantation and Toxicology.

Please contact LINK Healthcare on + 61 (2) 8401 9777 or www.linkhealthcare.co

Corporate and Media Enquiries:

Mr John Bacon
Chairman